Ami Fadia
Stock Analyst at Needham
(4.54)
# 294
Out of 5,182 analysts
332
Total ratings
50.47%
Success rate
29.08%
Average return
Main Sectors:
Stocks Rated by Ami Fadia
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines | Maintains: Buy | $145 → $186 | $131.67 | +41.26% | 29 | Apr 20, 2026 | |
| PRAX Praxis Precision Medicines | Reiterates: Buy | $510 | $330.99 | +54.08% | 18 | Apr 14, 2026 | |
| MPLT MapLight Therapeutics | Initiates: Buy | $37 | $30.64 | +20.76% | 1 | Apr 8, 2026 | |
| NBIX Neurocrine Biosciences | Reiterates: Buy | $185 | $128.04 | +44.49% | 18 | Apr 6, 2026 | |
| CNTA Centessa Pharmaceuticals | Downgrades: Hold | n/a | $39.51 | - | 2 | Mar 31, 2026 | |
| NMRA Neumora Therapeutics | Reiterates: Buy | $8 | $2.22 | +260.36% | 11 | Mar 31, 2026 | |
| BCYC Bicycle Therapeutics | Maintains: Buy | $24 → $15 | $4.77 | +214.47% | 22 | Mar 18, 2026 | |
| ATAI AtaiBeckley | Reiterates: Buy | $14 | $4.34 | +222.58% | 2 | Mar 9, 2026 | |
| IMRX Immuneering | Reiterates: Buy | $11 | $5.76 | +90.97% | 21 | Mar 9, 2026 | |
| GHRS GH Research | Maintains: Buy | $31 → $32 | $19.60 | +63.31% | 4 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $46 → $44 | $31.05 | +41.71% | 40 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $225 | $187.40 | +20.06% | 19 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $235 | $201.22 | +16.79% | 35 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $36.61 | - | 24 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $29 | $22.30 | +30.04% | 12 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $44 | $33.73 | +30.45% | 4 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $180.67 | - | 43 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $240 → $320 | $13.93 | +2,197.20% | 2 | Feb 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $63 → $75 | $25.55 | +193.54% | 7 | Jan 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $64 → $63 | $11.49 | +448.30% | 5 | Sep 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $31.26 | - | 9 | Oct 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $1.19 | +1,748.74% | 4 | Jan 3, 2018 |
Revolution Medicines
Apr 20, 2026
Maintains: Buy
Price Target: $145 → $186
Current: $131.67
Upside: +41.26%
Praxis Precision Medicines
Apr 14, 2026
Reiterates: Buy
Price Target: $510
Current: $330.99
Upside: +54.08%
MapLight Therapeutics
Apr 8, 2026
Initiates: Buy
Price Target: $37
Current: $30.64
Upside: +20.76%
Neurocrine Biosciences
Apr 6, 2026
Reiterates: Buy
Price Target: $185
Current: $128.04
Upside: +44.49%
Centessa Pharmaceuticals
Mar 31, 2026
Downgrades: Hold
Price Target: n/a
Current: $39.51
Upside: -
Neumora Therapeutics
Mar 31, 2026
Reiterates: Buy
Price Target: $8
Current: $2.22
Upside: +260.36%
Bicycle Therapeutics
Mar 18, 2026
Maintains: Buy
Price Target: $24 → $15
Current: $4.77
Upside: +214.47%
AtaiBeckley
Mar 9, 2026
Reiterates: Buy
Price Target: $14
Current: $4.34
Upside: +222.58%
Immuneering
Mar 9, 2026
Reiterates: Buy
Price Target: $11
Current: $5.76
Upside: +90.97%
GH Research
Mar 6, 2026
Maintains: Buy
Price Target: $31 → $32
Current: $19.60
Upside: +63.31%
Feb 25, 2026
Maintains: Buy
Price Target: $46 → $44
Current: $31.05
Upside: +41.71%
Feb 23, 2026
Reiterates: Buy
Price Target: $225
Current: $187.40
Upside: +20.06%
Jan 12, 2026
Maintains: Buy
Price Target: $210 → $235
Current: $201.22
Upside: +16.79%
Dec 8, 2025
Reiterates: Hold
Price Target: n/a
Current: $36.61
Upside: -
Nov 6, 2025
Maintains: Buy
Price Target: $28 → $29
Current: $22.30
Upside: +30.04%
Oct 29, 2025
Maintains: Buy
Price Target: $43 → $44
Current: $33.73
Upside: +30.45%
Sep 24, 2025
Reiterates: Hold
Price Target: n/a
Current: $180.67
Upside: -
Feb 1, 2021
Maintains: Outperform
Price Target: $240 → $320
Current: $13.93
Upside: +2,197.20%
Jan 21, 2021
Downgrades: Market Perform
Price Target: $63 → $75
Current: $25.55
Upside: +193.54%
Sep 17, 2020
Maintains: Outperform
Price Target: $64 → $63
Current: $11.49
Upside: +448.30%
Oct 1, 2018
Upgrades: Market Perform
Price Target: n/a
Current: $31.26
Upside: -
Jan 3, 2018
Initiates: Outperform
Price Target: $22
Current: $1.19
Upside: +1,748.74%